Biopharma financing during the second quarter of 2024 totaled $22.8bn from 272 deals. Of those, 29 reached $100m or more. The venture financings category made up most (32%) of the aggregate Q2 financing dollars (see Exhibit 1).
Financing Quarterly Statistics, Q2 2024
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2024
Listen to this article
During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.
Candid conversations with C-suite leaders.
More from Deal-Making
- • By
<p>Executive Summary</p> <p>An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker</p>
- • By
China has seen a “milestone year for the overseas launch of domestically produced innovative drugs.”
- • By
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
- • By
An interactive look at pharma, medtech and diagnostics deals made during July 2024. Data courtesy of Biomedtracker.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.